Parasite internal protein transport system

The parasite internal protein transport system is a critical cellular machinery in Plasmodium species, the causative agents of malaria, responsible for the trafficking and export of proteins essential for the parasite's survival and host cell remodeling. This system, which involves the endoplasmic reticulum (ER) and Golgi apparatus, is the primary target of the novel antimalarial drug ganaplacide (KAF156). By disrupting this transport network, drugs can induce ER expansion and inhibit the establishment of new permeation pathways, effectively killing the parasite at multiple stages, including the asexual blood stage and the transmission-blocking gametocyte stage. Mutations in the Plasmodium falciparum cyclic amine resistance locus (PfCARL), a key component of this system localized to the cis-Golgi, are a major driver of resistance to this class of compounds. Ganaplacide has recently demonstrated high cure rates in Phase 3 clinical trials, particularly when combined with lumefantrine, highlighting its potential as a next-generation antimalarial. Targeting this system represents a significant therapeutic strategy to overcome existing resistance to artemisinin-based therapies.

Other names

Plasmodium falciparum cyclic amine resistance locusPfCARLProtein trafficking systemER-Golgi transport system

Disruption of the internal protein transport system within the parasite, leading to the inhibition of protein trafficking, expansion of the endoplasmic reticulum, and eventual parasite death across multiple life cycle stages.